There has never been a more exciting time for patients suffering from Age-Related Macular Degeneration (ARMD) or for the many physicians who treat this disease.
Laser treatment was once the only treatment option available to destroy the abnormal blood vessel growth responsible for severe visual loss. The effectiveness was severely limited by poor visual results and a tendency for the blood vessels to grow back.
Current therapy with powerful medicines delivered directly into the eye, have all but replaced traditional laser therapy. These treatments are not only extremely effective in preventing further vision loss (up to 95%), but can offer up to a 35% chance of improving vision.
We could not have come this far in the treatment of ARMD were it not for CLINICAL TRIALS which carefully evaluated these medications and proved that they were both SAFE and EFFECTIVE. Were it not for the many dedicated patients who volunteered to take part in these trials, the general population and future generations would not have these wonderful therapies available today.
As part of The Retina Care Center’s commitment to offer our patients the most sophisticated retinal care, we recognize that not all patients respond well to traditional therapy. We also have patients who may be looking for better results than what standard therapy can offer. Regardless of motivation, it is this type of individual that might be interested in participating in a clinical trial investigating a new medication, surgical procedure, or treatment strategy.
Although clinical trials do not guarantee a cure, a better visual outcome, or even treatment with the study medication in question, patients understand that their commitment to these investigations may lead to the approval of even better treatments for retinal diseases such as ARMD, Diabetic Retinopathy, and Veno-occlusive diseases. These individuals share the common goal of lessening the burden of blindness for current and future generations.
The Retina Care Center is currently enrolling patients for the following major Clinical Trials (diseases in parenthesis):
PAGODA– Ranibizumab Port Delivery System (Diabetic Macular Edema)
OAKS– APL-2 (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
GALLEGO– RO7171009 (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
IONIS– IONIS-FB-LRx (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
RECLAIM2– Elamipretide (Geographic Atrophy Secondary to Age-Related Macular Degeneration)